Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11,465 Mln
Revenue (TTM)
$2,939 Mln
Net Profit (TTM)
$538 Mln
ROE
0.1 %
ROCE
11.4 %
P/E Ratio
21.6
P/B Ratio
2.5
Industry P/E
--
EV/EBITDA
15.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$33.3
EPS
$3.9
Face value
--
Shares outstanding
135,253,051
CFO
$1,783.21 Mln
EBITDA
$2,403.17 Mln
Net Profit
$1,293.16 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Globus Medical (GMED)
| -0.8 | -2.7 | 1.8 | 20.0 | 18.7 | 7.1 | 14.0 |
|
BSE Sensex
| -9.4 | -8.1 | -9.3 | 3.4 | 9.8 | 9.0 | 12.0 |
|
S&P Midcap 400
| 0.5 | -5.8 | 1.7 | 13.2 | 12.3 | 4.8 | 9.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Globus Medical (GMED)
| 5.6 | 54.7 | -28.2 | 2.9 | 10.7 | 10.8 | 36.0 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Globus Medical (GMED)
|
86.6 | 11,465.4 | 2,938.9 | 537.9 | 18.3 | 12.3 | 21.6 | 2.5 |
| 108.5 | 187,721.9 | 44,328.0 | 6,524.0 | 20.0 | 13.1 | 29 | 3.6 | |
| 158.1 | 57,735.4 | 21,923.0 | 1,757.0 | 12.0 | 6.9 | 26 | 1.8 | |
| 71.3 | 102,581.0 | 20,074.0 | 2,886.0 | 14.7 | 12.5 | 35.6 | 4.2 | |
| 191.5 | 132,461.4 | 24,568.0 | 3,614.0 | 18.3 | 7.1 | 37.2 | 2.9 | |
| 73.1 | 8,896.5 | 13,184.0 | 398.0 | 5.2 | 12 | 23.1 | 2.7 | |
| 477.7 | 167,678.3 | 10,064.7 | 2,856.0 | 29.3 | 16.7 | 59.8 | 9.5 | |
| 27.4 | 26,640.6 | 17,834.0 | 895.0 | 8.5 | 7.8 | 26 | 2.1 | |
| 345.8 | 128,878.1 | 25,116.0 | 3,246.0 | 17.9 | 15.1 | 40.1 | 5.8 | |
| 464.7 | 172,506.1 | 44,556.0 | 6,737.0 | 19.5 | 13.1 | 26.2 | 3.3 |
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle... screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania. Read more
Co-Founder & Executive Chairman
Mr. David C. Paul
Co-Founder & Executive Chairman
Mr. David C. Paul
Headquarters
Audubon, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Globus Medical (GMED) is $86.58 (NYSE) as of 18-Mar-2026 16:00 EDT. Globus Medical (GMED) has given a return of 18.65% in the last 3 years.
The P/E ratio of Globus Medical (GMED) is 21.63 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
22.27
|
2.62
|
|
2024
|
112.21
|
2.77
|
|
2023
|
60.29
|
1.85
|
|
2022
|
39.92
|
4.11
|
|
2021
|
50.42
|
4.32
|
The 52-week high and low of Globus Medical (GMED) are Rs 101.40 and Rs 51.79 as of 19-Mar-2026.
Globus Medical (GMED) has a market capitalisation of $ 11,465 Mln as on 13-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Globus Medical (GMED), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.58
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.